A review of drugs that contribute to bleeding risk in general dental practice

L Teoh, G Moses, M J McCullough, L Teoh, G Moses, M J McCullough

Abstract

The risk of postoperative bleeding is a daily concern for many general dental practitioners. A thorough medical and medication history must be taken to consider all risk factors, particularly drugs, that contribute to bleeding risk. While the risk from drugs such as aspirin, warfarin and clopidogrel are well known, the extent to which new antiplatelet agents and direct oral anticoagulants affect bleeding risk is less well understood. In addition, there are drugs other than antithrombotics, such as antidepressants and complementary medicines that also impair haemostasis. The aim of this paper is to provide dentists with an updated overview of the drugs commonly encountered in general dental practice that can contribute to a patient's postoperative bleeding risk.

Keywords: Anticoagulant; anti-thrombotic; antiplatelet; bleeding risk; dentistry.

© 2020 Australian Dental Association.

References

    1. Oral and Dental Expert Group. Therapeutic guidelines: Oral and dental version 3. Melbourne, Australia: Therapeutic Guidelines Ltd, 2019.
    1. Clinical Excellence Commission. Guidelines on Perioperative Management of Anticoagulant and Antiplatelet Agents.2018.
    1. Scottish Dental Clinical Effectiveness Program. Management of dental patients taking anticoagulants or antiplatelet drugs. Dundee, UK: National Dental Advisory Committee, 2015.
    1. Rang HP, Dale MM, Ritter JM Pharmacology. 4th edn. Edinburgh, New York: Churchill Livingstone, 1999:830pp.
    1. Dave HD, LaPelusa A. Physiology, hemostasis. Treasure Island, FL: StatPearls, 2019.
    1. Toschi V, Lettino M. Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol 2011;72:563-580.
    1. Thean D, Alberghini M. Anticoagulant therapy and its impact on dental patients: a review. Aust Dent J 2016;61:149-156.
    1. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964-1977.
    1. Expert Advisory Committee. Australian Medicines Handbook.2019.
    1. Pototski M, Amenabar JM. Dental management of patients receiving anticoagulation or antiplatelet treatment. J Oral Sci 2007;49:253-258.
    1. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:1036-1046.
    1. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018;379:1519-1528.
    1. McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018;379:1509-1518.
    1. McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018;379:1499-1508.
    1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
    1. Clopidogrel. 2019. Available at: . Accessed 8 October 2019.
    1. Asasantin SR. Dipyridamole, Aspirin. 2019. Available at: . Accessed 8 October 2019.
    1. Johnston S. An evidence summary of the management of the care of patients taking novel oral antiplatelet drugs undergoing dental surgery. J Am Dent Assoc 1939;2016:271-277.
    1. Ticagrelor. 2019. Available at: . Accessed 8 October 2019.
    1. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
    1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
    1. Heparin Sodium. 2019. Available at: . Accessed 8 October 2019.
    1. Salam S, Yusuf H, Milosevic A. Bleeding after dental extractions in patients taking warfarin. Br J Oral Maxillofac Surg 2007;45:463-466.
    1. Australian Government Department of Health. PBS and RPBS Section 85 Date of Processing and Date of Supply Data 2017. Available at: . Accessed 1 August 2019.
    1. Lanau N, Mareque J, Giner L, Zabalza M. Direct oral anticoagulants and its implications in dentistry. A review of literature. J Clin Exp Dent 2017;9:e1346-e1354.
    1. Johnston S. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. Int J Oral Maxillofac Surg 2016;45:618-630.
    1. Dabigatran. 2019. Available at: . Accessed 8 October 2019.
    1. Fortier K, Shroff D, Reebye UN. Review: An overview and analysis of novel oral anticoagulants and their dental implications. Gerodontology 2018;35:78-86.
    1. Rivaroxaban. 2019. Available at: . Accessed 8 October 2019.
    1. Apixaban. 2019. Available at: . Accessed 8 October 2019.
    1. Wahl MJ. Dental surgery and antiplatelet agents: bleed or die. Am J Med 2014;127:260-267.
    1. Sambrook P. Dentistry concerns for patients taking anticoagulants and antiplatelet drugs. Aust Prescr 2018;41:116.
    1. Bensi C, Belli S, Paradiso D, Lomurno G. Postoperative bleeding risk of direct oral anticoagulants after oral surgery procedures: a systematic review and meta-analysis. Int J Oral Maxillofac Surg 2018;47:923-932.
    1. Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122:e146-e55.
    1. Doganay O, Atalay B, Karadag E, Aga U, Tugrul M. Bleeding frequency of patients taking ticagrelor, aspirin, clopidogrel, and dual antiplatelet therapy after tooth extraction and minor oral surgery. J Am Dent Assoc 1939;2018:132-138.
    1. Olmos-Carrasco O, Pastor-Ramos V, Espinilla-Blanco R, et al. Hemorrhagic complications of dental extractions in 181 patients undergoing double antiplatelet therapy. J Oral Maxillofac Surg 2015;73:203-210.
    1. Kelley BP, Bennett KG, Chung KC, Kozlow JH. Ibuprofen may not increase bleeding risk in plastic surgery: a systematic review and meta-analysis. Plast Reconstr Surg 2016;137:1309-1316.
    1. Napenas JJ, Hong CH, Kempter E, Brennan MT, Furney SL, Lockhart PB. Selective serotonin reuptake inhibitors and oral bleeding complications after invasive dental treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:463-467.
    1. Shin D, Oh YH, Eom CS, Park SM. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol 2014;261:686-695.
    1. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163:59-64.
    1. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999;319:1106-1109.
    1. Sarma A, Horne MK 3rd. Venlafaxine-induced ecchymoses and impaired platelet aggregation. Eur J Haematol 2006;77:533-537.
    1. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008;65:795-803.
    1. Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015;13:42-50.
    1. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014;109:811-819.
    1. Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf 2005;4:337-344.
    1. Leong C, Alessi-Severini S, Enns MW, et al. Cerebrovascular, cardiovascular, and mortality events in new users of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors: a propensity score-matched population-based study. J Clin Psychopharmacol 2017;37:332-340.
    1. Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res 2017;118:19-32.
    1. Therapeutic Goods Administration Department of Health. An overview of the regulation of complementary medicines in Australia. Available at: . Accessed 30 October 2019.
    1. von Conrady DM, Bonney A. Patterns of complementary and alternative medicine use and health literacy in general practice patients in urban and regional Australia. Aust Fam Physician 2017;46:316-320.
    1. Reid R, Steel A, Wardle J, Trubody A, Adams J. Complementary medicine use by the Australian population: a critical mixed studies systematic review of utilisation, perceptions and factors associated with use. BMC Complement Altern Med 2016;16:176.
    1. Abebe W. Review of herbal medications with the potential to cause bleeding: dental implications, and risk prediction and prevention avenues. EPMA J 2019;10:51-64.
    1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-1575.
    1. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27:391-401.
    1. Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. CMAJ 2006;174:1281-1282.
    1. Page RL 2nd, Lawrence JD. Potentiation of warfarin by Dong Quai. Pharmacotherapy 1999;19:870-876.
    1. Yin ZZ, Zhang LY,Xu LN. The effect of Dang-Gui (Angelica sinensis) and its ingredient ferulic acid on rat platelet aggregation and release of 5-HT (author's transl). Yao Xue Xue Bao 1980;15:321-326.
    1. Natural Medicines Database. Available at: . Accessed 20 December 2019.
    1. De La Cruz JP, Martin-Romero M, Carmona JA, Villalobos MA. Sanchez de la Cuesta F. Effect of evening primrose oil on platelet aggregation in rabbits fed an atherogenic diet. Thromb Res 1997;87:141-149.
    1. Yang C, Li L, Yang L, Lu H, Wang S, Sun G. Anti-obesity and Hypolipidemic effects of garlic oil and onion oil in rats fed a high-fat diet. Nutr Metab (Lond) 2018;15:43.
    1. Bordia A. Effect of garlic on human platelet aggregation in vitro. Atherosclerosis 1978;30:355-360.
    1. Abebe W. Herbal supplements having the potential to interfere with blood clotting. GDA Action 2003;22:23-24.
    1. Shankland WE 2nd. Four common herbs seen in dental practice: properties and potential adverse effects. Cranio 2009;27:118-124.
    1. Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evid Based Complement Alternat Med 2014;957362.
    1. Srivastava KC. Aqueous extracts of onion, garlic and ginger inhibit platelet aggregation and alter arachidonic acid metabolism. Biomed Biochim Acta 1984;43:S335-346.
    1. Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987;1:248-251.
    1. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108.
    1. Kuo SC, Teng CM, Lee JC, Ko FN, Chen SC, Wu TS. Antiplatelet components in Panax ginseng. Planta Med. 1990;56:164-167.
    1. Park HJ, Lee JH, Song YB, Park KH. Effects of dietary supplementation of lipophilic fraction from Panax ginseng on cGMP and cAMP in rat platelets and on blood coagulation. Biol Pharm Bull 1996;19:1434-1439.
    1. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-2211.
    1. Lin PC, Jones SO, McGlasson DL. Effects of glucosamine and Celadrin on platelet function. Clin Lab Sci 2010;23:32-36.
    1. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 1995;52:223-227.
    1. Jantan I, Raweh SM, Sirat HM, et al. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. Phytomedicine 2008;15:306-309.
    1. Prakash P, Misra A, Surin WR, et al. Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 2011;127:111-118.
    1. Memorial Sloan Kettering Cancer Center. Tumeric. Available at: . Accessed 20 December 2019.
    1. Psychotropic Guidelines Expert Group. Therapeutic guidelines psychotropic version 7. Melbourne Australia: Therapeutic Guidelines Pty Ltd, 2013.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever